Hijioka, S., Honma, Y., Machida, N., Mizuno, N., Hamaguchi, T., Boku, N., Sadachi, R., Hiraoka, N., Okusaka, T., Hirano, H., Boku, S., Ikeda, M., Takeuchi, S., Fukushima, N., Kojima, M., Mitome, N., Sano, Y., Yoshikawa, T., Kanemitsu, Y., Ueno, M. (2025). A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.652